Regeneron Pharmaceuticals Announces EMA Endorsement for Extended Libtayo Dosing
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) confirmed that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion supporting an alternative dosing schedule for its checkpoint‑inhibitor drug Libtayo (cemiplimab). The recommendation applies to all indications currently approved for the product.
Key Elements of the CHMP Recommendation
- Initial Phase: Patients receive 350 mg of Libtayo as a 30‑minute intravenous infusion every 12 weeks.
- Extended Phase: Following the initial 12‑week regimen, the drug can be administered at 700 mg via a 30‑minute infusion every six weeks.
- Infusion Time Flexibility: The CHMP also suggested that the infusion time for the 350 mg dose could be shortened to 15–30 minutes after a well‑tolerated first dose.
The decision aims to streamline treatment schedules and potentially improve patient adherence without compromising efficacy.
Market Context
- The checkpoint‑inhibitor refractory cancer market is projected to grow to USD 133.96 billion by 2035, with a compound annual growth rate of 12.13% from 2025 to 2035 (Credence Research).
- Regeneron’s Libtayo is a significant contributor to the company’s oncology portfolio, and the new dosing option could enhance its competitiveness in this expanding market.
Financial Snapshot (as of 2026‑10‑15)
- Close Price: USD 790.74
- 52‑Week High: USD 859.34 (2026‑09‑02)
- 52‑Week Low: USD 572.75 (2025‑10‑22)
- Market Cap: USD 81.4 billion
- Price/Earnings Ratio: 19.76
The EMA endorsement is expected to support Regeneron’s valuation and may influence investor sentiment following recent market volatility, as seen in broader Nasdaq movements on 2026‑10‑15.
